Stephen Pagnotta Headshot_6.29.23
That Price Is WAC: Boehringer’s Push For Access To Humira Biosimilars
By Ben ComerChief Editor, Life Science Leader
Monday, January 29, 2024
Boehringer Ingelheim's biosimilar commercial brand leader explains the company's two-tier pricing approach with Cyltezo, an interchangeable Humira biosimilar, and what new FDA guidance on interchangeability means for patients and physicians.  Continue Reading..
Ben Comer_2022_1

Ben Comer

Ben Comer is chief editor of Life Science Leader magazine. He has covered the biopharmaceutical, medtech and medical device industries for 15 years as a reporter and editor, and worked as a senior manager in PwC’s Health Research Institute. Comer was most recently executive editor at In Vivo magazine, where he wrote feature stories, executive profiles and articles ranging from pre-clinical biotech strategy, fundraising, supply chain, manufacturing, and regulatory issues, to global commercialization efforts, market access and environmental, social and governance topics. He has interviewed hundreds of executives and experts at biopharmaceutical and life science companies, academic institutions, law firms, patient advocacy groups, payer and provider organizations, industry trade associations and regulatory bodies. Comer has presented and moderated panels at dozens of industry conferences, convened webcasts with industry leaders, and published news articles and other writing in Scrip, Pink Sheet, MedTech Insight, Generics Bulletin, Pharmaceutical Executive, PharmTech, Applied Clinical Trials, Medical Marketing & Media and PR Week, among others. Comer is a graduate of the College of Charleston and has worked in compounding pharmacies as a certified technician. You can find him on Twitter @BenMComer.